Adherex Technologies, Inc. (AMEX: ADH), a biopharmaceutical company, is focused on discovering and developing novel cancer therapeutics. They currently have a number of products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Adherex’s mission is to become a leading developer of innovative treatments that address important unmet medical needs in cancer. For further information, visit the Company’s web site at www.adherex.com.
- 17 years ago
QualityStocks
Adherex Technologies, Inc. (AMEX: ADH)
Tags Rodman & Renshaw
Related Post
-
Strawberry Fields REIT Inc.’s (NYSE AMERICAN: STRW) CEO, Moishe Gubin, Reflects on the Company’s Milestones on Bell2Bell Podcast
Strawberry Fields REIT, Inc., is a self-administered real estate investment trust, focused on the acquisition…
-
SEGG Media Corporation (NASDAQ: SEGG) Undergoes Expansion, Experiences New Growth, and Unveils a New Website
SEGG Media has recently expanded its offering by launching SEGG Digital and SEGG Productions. The…
-
Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential
Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option…